Brokerages expect Achieve Life Sciences Inc (NASDAQ:ACHV) to announce earnings of ($0.33) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Achieve Life Sciences’ earnings. Achieve Life Sciences reported earnings of ($1.82) per share in the same quarter last year, which would indicate a positive year over year growth rate of 81.9%. The business is scheduled to issue its next quarterly earnings report on Wednesday, August 14th.
On average, analysts expect that Achieve Life Sciences will report full-year earnings of ($1.70) per share for the current fiscal year, with EPS estimates ranging from ($2.19) to ($1.20). For the next year, analysts anticipate that the business will report earnings of ($1.54) per share, with EPS estimates ranging from ($1.91) to ($1.16). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Achieve Life Sciences.
Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter.
ACHV has been the topic of several recent analyst reports. LADENBURG THALM/SH SH set a $20.00 price objective on shares of Achieve Life Sciences and gave the company a “buy” rating in a research report on Tuesday, June 11th. Maxim Group started coverage on shares of Achieve Life Sciences in a research note on Friday, June 14th. They set a “buy” rating and a $6.00 price objective for the company.
In other Achieve Life Sciences news, CEO Richard Alistair Stewart bought 17,500 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The shares were purchased at an average price of $3.61 per share, for a total transaction of $63,175.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Armistice Capital Master Fund bought 12,813 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were acquired at an average price of $3.80 per share, for a total transaction of $48,689.40. The disclosure for this purchase can be found here. Corporate insiders own 6.80% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Worth Venture Partners LLC grew its position in Achieve Life Sciences by 180.1% during the fourth quarter. Worth Venture Partners LLC now owns 89,632 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 57,632 shares in the last quarter. Searle & CO. acquired a new position in shares of Achieve Life Sciences in the 1st quarter worth approximately $237,000. Finally, Vanguard Group Inc boosted its holdings in shares of Achieve Life Sciences by 169.3% in the 3rd quarter. Vanguard Group Inc now owns 35,468 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 22,299 shares in the last quarter. 16.20% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:ACHV traded down $0.04 during trading hours on Tuesday, hitting $2.07. 120,500 shares of the stock traded hands, compared to its average volume of 998,303. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.03. Achieve Life Sciences has a 1 year low of $1.04 and a 1 year high of $6.10. The stock has a market capitalization of $15.93 million, a P/E ratio of -0.57 and a beta of 2.66. The firm has a 50 day moving average of $3.52.
About Achieve Life Sciences
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.
Recommended Story: Recession
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.